Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Change in Accured Expenses (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Change in Accured Expenses for 16 consecutive years, with $79597.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 245.93% year-over-year to $79597.0, compared with a TTM value of -$853006.0 through Oct 2025, up 29.35%, and an annual FY2025 reading of -$853006.0, up 29.35% over the prior year.
  • Change in Accured Expenses was $79597.0 for Q4 2025 at Pharma-Bio Serv, up from -$121631.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $360860.0 in Q3 2021 and bottomed at -$764001.0 in Q2 2021.
  • Average Change in Accured Expenses over 5 years is -$155186.8, with a median of -$102508.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses skyrocketed 305.27% in 2023, then tumbled 1618.45% in 2024.
  • Year by year, Change in Accured Expenses stood at $189423.0 in 2021, then tumbled by 144.02% to -$83385.0 in 2022, then crashed by 285.47% to -$321427.0 in 2023, then soared by 83.03% to -$54545.0 in 2024, then surged by 245.93% to $79597.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for PBSV at $79597.0 in Q4 2025, -$121631.0 in Q3 2025, and -$597831.0 in Q2 2025.